Abstract:ID 92341 Poster Board 545 As one of the most successful set of targets for therapeutic development, GPCRs are activated by diverse array of ligands to induce signaling through multiple distinct pathways, yielding varied biological and physiological responses.The pharmacological concept of biased signaling (functional selectivity) describes the ability of select ligands to preferentially activate one receptor-mediated signaling pathway over others. The development of functionally selective ligands holds significant implications for the development of drugs with fewer side effects. Antibodies (Abs) are useful tools for targeting cell surface proteins; however, developing signaling competent GPCR-targeted Abs remains challenging and is often unsuccessful. Camelid single domain antibodies (or nanobodies, Nbs) have been shown to target epitopes in GPCRs not accessible to conventional Abs. However, it remains difficult to identify Nbs that can directly activate GPCR signaling. We developed a unique methodology in our lab to link PTHR1-binding Nbs with synthetic ligands to provide semi-synthetic conjugates that directly modulate GPCR function to overcome this hurdle. Nb-ligand conjugates were prepared through a combination of enzymatic protein labeling, solid-phase peptide (ligand) synthesis, and chemoselective conjugation chemistry. Unlike conventional approaches that modify the core ligand structure, our strategy involves conjugating the ligand to a nanobody that tethers it to the targeted receptor. The activity of Nb-ligand conjugates were assessed in a series of pharmacological assay, including cAMP production, G-protein dissociation, and β-arrestin translocation assays. The linkage of a weakly active PTHR1 ligand fragment (PTH 1-11 ) to a Nb that bound to PTHR1 extracellular domain caused a substantial enhancement in potency for signaling through the G αs pathway. We also assessed duration of signaling in a cAMP "washout" assay. Results revealed that Nb-peptide conjugates induced prolonged cAMP responses upon ligand washout relative to an analogue of a human PTHR1 drug PTH 1-11 . In contrast, these conjugates displayed a drastically impaired capacity to induce recruitment of β-arrestin to the plasma membrane or to early endosomes or to signal via G αq. These findings mark the Nb-PTH 1-11 conjugates as the most biased agonist of PTHR1 reported to date. We also performed mechanistic studies of the origin of bias, revealing that the Nb-PTH 1-11 conjugates can activate signaling through a mode that involves two receptor protomers (activation in trans ). This mechanism is qualitatively distinct from that of conventional PTHR1 ligands such as PTH 1-34 or PTH 1-11 . The platform described here has the potential to advance our understanding of diseases associated with PTHR1 by enabling selective modulation of individual signaling pathways. Work is underway to expand this platform to generate Nb-based biased agonists of other GPCRs including opioid receptors. Facile generation of biased agonists offers the prospect of probing the utility of pathway-selective signaling for the treatment GPCR-associated diseases. This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

TLR4 biased small molecule modulators

Small-Molecule Modulators of Toll-like Receptors

Targeting Toll-Like Receptors With Small Molecule Agents

Recent progress in the development of Toll-like receptor (TLR) antagonists

TLR10: Insights, controversies and potential utility as a therapeutic target

Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor

Signalling bias in new drug discovery: detection, quantification and therapeutic impact

TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Small-Molecule TLR8 Antagonists Via Structure-Based Rational Design.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

[Research Progress in Signal Bias of G Protein-Coupled Receptor and Its Mechanism].

Progress on the development of Class A GPCR‐biased ligands

Nanobody Tethering Enables Highly Biased Agonism for GPCR Ligands

From Molecular Mechanisms to Clinical Applications

The GLP-1R as a model for understanding and exploiting biased agonism in next generation medicines.

Highly biased agonism for GPCR ligands via nanobody tethering

Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism

Exploring Species-Specificity in TLR4/MD-2 Inhibition with Amphiphilic Lipid A Mimicking Glycolipids

GPCR signaling bias: an emerging framework for opioid drug development

Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex

Therapeutic Targeting of TLR4 for Inflammation, Infection, and Cancer: A Perspective for Disaccharide Lipid A Mimetics